A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia

Category Primary study
JournalLeukemia & lymphoma
Year 2023
This article has no abstract
Epistemonikos ID: 5521d82e6347864f64a5d06624c4fc16627bff27
First added on: Apr 29, 2024